US Broker Ratings

Addus HomeCare Corporation (ADUS) Stock Analysis: Unlocking a 23.35% Upside Potential in the Healthcare Sector

Addus HomeCare Corporation (NASDAQ: ADUS) is an intriguing player in the healthcare sector, specializing in providing essential personal care services to some of the most vulnerable populations in the United..

Guardian Pharmacy Services, Inc (GRDN) Stock Analysis: Exploring a 31.79% Potential Upside

Guardian Pharmacy Services, Inc (GRDN) is positioned at the intersection of healthcare and technology, providing essential services to long-term care facilities (LTCFs) across the United States. With a market capitalization..

Arcellx, Inc. (ACLX) Stock Analysis: Exploring a 69% Upside Potential with Strong Buy Ratings

Arcellx, Inc. (NASDAQ: ACLX) is a promising player in the biotechnology sector, primarily focused on breakthrough immunotherapies for cancer and other formidable diseases. This U.S.-based company, headquartered in Redwood City,..

Disc Medicine, Inc. (IRON): Analyst Consensus and 84% Upside Potential Ignite Investor Interest

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, is gaining attention in the investment community, particularly among those focused on biotechnology opportunities within the healthcare..

Novavax, Inc. (NVAX) Stock Analysis: Exploring a Potential 103% Upside

For investors with an appetite for high-risk, high-reward opportunities, Novavax, Inc. (NASDAQ: NVAX) offers a compelling narrative. With a potential upside of 103.16% based on analyst ratings, this biotechnology firm..

Bausch Health Companies Inc. (BHC) Stock Analysis: Navigating a 3.11% Potential Upside with Strategic Insights

Bausch Health Companies Inc. (NYSE: BHC) represents an intriguing opportunity in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With a market capitalization of $2.55 billion,..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Significant Upside Potential with an 87% Increase Forecasted

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a prominent player in the biotechnology sector, is gaining notable attention from investors due to its innovative approach in treating severe allergic reactions. Based in..

PACS Group, Inc. (PACS)

⚠️ No article content returned.

..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 126.82% Potential Upside Amidst Strong Buy Ratings

Ultragenyx Pharmaceutical Inc. (RARE), a prominent player in the biotechnology sector, is making waves with its focus on rare and ultra-rare genetic diseases. Headquartered in Novato, California, Ultragenyx has carved..

Indivior PLC (INDV) Investor Outlook: Exploring a 22% Potential Upside with Robust Analyst Confidence

Indivior PLC (INDV), a key player in the healthcare sector, is gaining attention with a compelling 22.19% potential upside. Situated within the Drug Manufacturers – Specialty & Generic industry, Indivior..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Exploring a 141% Potential Upside in the Biotech Sector

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) stands out in the biotechnology sector with a promising portfolio of targeted oncology therapeutics. With a market capitalization of $1.85 billion, this precision medicine company..

Alignment Healthcare, Inc. (ALHC) Growth Potential: Analyst Ratings and a 38.68% Upside

Alignment Healthcare, Inc. (NASDAQ: ALHC), a prominent player in the healthcare sector specializing in Medicare Advantage plans, is capturing investor attention with its remarkable growth prospects and analyst optimism. Based..

Pulse Biosciences, Inc (PLSE) Stock Analysis: Navigating Uncharted Territory with a $1.06 Billion Market Cap

Pulse Biosciences, Inc. (NASDAQ: PLSE) stands out in the healthcare sector, specifically within the medical instruments and supplies industry, with its innovative approach to bioelectric medicine. Headquartered in Miami, Florida,..

Certara, Inc. (CERT) Stock Analysis: Navigating a 44% Potential Upside in the Healthcare Sector

For investors with a keen eye on the healthcare sector, Certara, Inc. (NASDAQ: CERT) represents an intriguing opportunity, particularly given its potential upside of 44.35% based on the current average..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Exploring the 73.52% Potential Upside in Biotech

For investors with an eye toward the biotechnology sector, Xenon Pharmaceuticals Inc. (NASDAQ: XENE) presents a compelling case, not just for its innovative pipeline but also for its significant potential..

ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: Exploring a 25% Upside Potential

ANI Pharmaceuticals, Inc. (ANIP) is a standout player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. Headquartered in Baudette, Minnesota, this biopharmaceutical company boasts a..

Select Medical Holdings Corp (SEM) Stock Analysis: Eyeing a 38% Potential Upside with Robust Analyst Ratings

Select Medical Holdings Corporation (NYSE: SEM) has emerged as a notable player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.9 billion,..

Dynavax Technologies Corporation (DVAX) Stock Analysis: Evaluating the 125% Upside Potential

Investors are always on the lookout for promising opportunities in the healthcare sector, and Dynavax Technologies Corporation (NASDAQ: DVAX) has been catching eyes with its substantial potential upside. With its..

CONMED Corporation (CNMD) Stock Analysis: Exploring a Potential 28% Upside in the Medical Devices Sector

CONMED Corporation, trading under the ticker CNMD, stands as a noteworthy player in the medical devices sector within the healthcare industry. With a market capitalization of $1.61 billion, this U.S.-based..

Artivion, Inc. (AORT) Stock Analysis: A Promising Buy With 8% Upside Potential

Artivion, Inc. (AORT), a significant player in the medical devices sector, presents a compelling opportunity for investors seeking growth in the healthcare industry. With a market capitalization of $1.42 billion,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds